Xenetic Biosciences is trading at $1.84, up 8.24%, with broader market gains potentially contributing.
- No new company-specific announcement dated October 26 was identified; the latest company news was an October 15 update on the first patient dosed in a DNase-and-CAR-T study.
- Initial efficacy data from the study are expected in Q2 2027.
- Supplied market context showed the S&P 500 up 0.72% and Nasdaq up 1.03%; no volume or activity data was provided.